MEDI:GATE NEWS Bridge Biotherapeutics Begins Administration of Patients in Clinical Participation of BBT-176, a Next-Generation New Lung Cancer Drug Candidate
Thyroid cancer, the number one cancer incidence rate in Korea, requires long-term follow-up after surgery